Fierce Pharma
FEBRUARY 14, 2024
FDA unleashes multiple warning letters targeting insanitary manufacturing and online sales of unapproved Mounjaro, Ozempic fkansteiner Wed, 02/14/2024 - 05:10
PharmaTimes
FEBRUARY 14, 2024
The aggressive type of cancer accounts for 13% of all lung cancer cases worldwide
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 14, 2024
Over the last month, for those watching HBO’s macabre “True Detective Night Country”—a TV series set in a harsh, sunless winter in a fictional Alaskan town—a continual theme is frostbite. | The FDA has approved the first medicine for severe frostbite. The U.S. regulator has signed off on Johnson & Johnson’s Aurlumyn (iloprost), an injected treatment to reduce the risk of amputation of the fingers or toes.
MedCity News
FEBRUARY 14, 2024
Ipsen’s Onivyde is now FDA approved as a first-line treatment for metastatic pancreatic cancer, triggering a milestone payment to Merrimack Pharmaceuticals, the drug’s original developer. Merrimack plans to dissolve operations but its shareholders will receive payouts from the Ipsen payment.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
FEBRUARY 14, 2024
With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion. | With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion.
MedCity News
FEBRUARY 14, 2024
Most hospitals and payers have publicly posted their pricing information, but experts think that data will remain mostly useless for consumers for at least another five years. Now that the data is available, healthcare software companies must step in and build tools that are personalized and easy to use. That way, consumers can eventually use price transparency data to shop for care.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 14, 2024
When striving for health equity, organizations need to adopt new methods and a new mindset in order to steer clear of using SDoH as a buzzword, and instead hit the mark of health equity results.
Fierce Pharma
FEBRUARY 14, 2024
Even as Australia’s CSL continues to grow, the company’s ambitions for its kidney disease and iron deficiency outfit Vifor Pharma—now known as CSL Vifor—have become more muted. | Even as Australia’s CSL continues to grow, the company’s ambitions for its kidney disease and iron deficiency outfit Vifor Pharma—now known as CSL Vifor—have become more muted.
MedCity News
FEBRUARY 14, 2024
Omada’s newly expanded GLP-1 Care Track provides tailored exercise plans, support for getting off of GLP-1s and calorie tracking. It also offers insight into who is responding to GLP-1s and who is engaging in Omada’s program.
Fierce Pharma
FEBRUARY 14, 2024
Sage Therapeutics and Biogen may not have the broad label that they had hoped for with Zurzuvae, but the two companies are still touting the med’s initial launch performance in postpartum depressio | Sage Therapeutics and Biogen may not have the broad label that they had hoped for with Zurzuvae, but the two companies are touting the med’s initial launch performance in postpartum depression.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
FEBRUARY 14, 2024
Here’s the audio of Episode 1 of the newly-launched show Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare.
pharmaphorum
FEBRUARY 14, 2024
Eicos Sciences' Aurlumyn has become the first FDA-approved drug treatment to prevent amputations in cases of severe frostbite
MedCity News
FEBRUARY 14, 2024
2024 presents an exciting yet challenging landscape for global pharma marketers. Prioritizing digital transformation, adopting patient-centric strategies, navigating regulatory complexities, investing in innovative content marketing, and fostering global collaboration position pharmaceutical marketers to make a lasting impact in an ever-evolving industry.
pharmaphorum
FEBRUARY 14, 2024
Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
FEBRUARY 14, 2024
A comprehensive approach to obesity management goes beyond prescribing medications for a quick fix.
European Pharmaceutical Review
FEBRUARY 14, 2024
Gilead Sciences has agreed to acquire CymaBay Therapeutics for a total equity value of $4.3 billion. Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). This is based on data from the Phase III RESPONSE trial. The company shared that seladelpar is an oral, selective peroxisomeproliferator-activated receptor delta (PPARδ) agonist.
PharmaTimes
FEBRUARY 14, 2024
The report includes five recommendations for the government to address these issues
European Pharmaceutical Review
FEBRUARY 14, 2024
The development of drug products containing live anaerobic bacterial strains as the active pharmaceutical ingredient and where potency and shelf-life is typically associated with viable cell quantification, poses unique challenges when compared to both small and large molecule development therapeutics. It is the uniqueness of the strain and perceived inter-cellular variations (sub-populations) resulting from high viable cell densities during growth (fermentation) and the subsequent harvest and d
Pharmaceutical Technology
FEBRUARY 14, 2024
A bipartisan group of lawmakers is seeking an investigation and sanctions against WuXi given alleged connections to the Chinese military.
European Pharmaceutical Review
FEBRUARY 14, 2024
A report by Allied Market Research predicts that the global pharmaceutical suspension market will reach $83.8 billion by 2032. Having valued $55.5 billion in 2022, the research expected that the market will reach a CAGR of 4.2 percent between 2023 and 2032. Factors driving the global pharmaceutical suspension market One of the main factors anticipated to propel the growth of the pharmaceutical suspension market is the availability of generic pharmaceutical suspensions, the research asserted.
pharmaphorum
FEBRUARY 14, 2024
UK patients very concerned about access to diagnostics Phil.
Pharmacy Times
FEBRUARY 14, 2024
Despite the growth in vaccine and antibody development for combatting RSV, lower income countries may not reap the benefits.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
pharmaphorum
FEBRUARY 14, 2024
Venture capital group Earlybird has launched its second health fund with $185 million to fund companies in the health technology area
Pharmaceutical Technology
FEBRUARY 14, 2024
The partnership will focus on designing molecular glues for unspecified therapeutic targets.
Pharmacy Times
FEBRUARY 14, 2024
Continued doses of denosumab reduced the incidence of diabetes by more than 1000 patients compared to an initial dose alone.
Pharmaceutical Technology
FEBRUARY 14, 2024
The FDA has issued warning letters to two online sellers for selling unapproved versions of semaglutide and tirzepatide.
Pharmacy Times
FEBRUARY 14, 2024
Researchers will continue to research how lantibiotic’s antimicrobial effects can be harnessed for good.
Pharmaceutical Technology
FEBRUARY 14, 2024
The US FDA has granted fast track designation to Edgewise Therapeutics’ EDG-5506 aimed at treating Duchenne muscular dystrophy.
pharmaphorum
FEBRUARY 14, 2024
Exscientia has fired its founder and CEO Dr Andrew Hopkins over “inappropriate relationships” with employees, as chair David Nicholson resigns
Pharmacy Times
FEBRUARY 14, 2024
The approval of irinotecan liposome offers an improved first-line treatment option for individuals diagnosed with metastatic pancreatic adenocarcinoma.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
306 
Let's personalize your content